Alyeska Investment Group
NUVB icon

Alyeska Investment Group’s Nuvation Bio NUVB Stock Holding History

Alyeska Investment Group’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000,000
Closed -$10.4M – 806
2021
Q1 		$10.4M Buy
1,000,000
+928,409
+1,297% +$10.4M 0.13% 195
2020
Q4 		$838K Buy
+71,591
New +$745K 0.01% 425

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Alyeska Investment Group's NUVB Position: Q2 2021 in Review

Alyeska Investment Group sold out of Nuvation Bio (NUVB) in Q2 2021, closing a stake of 1,000,000 shares — an estimated $10.4M sold.

Alyeska Investment Group first reported a position in NUVB in Q4 2020 and held it in 2 quarters. The position peaked at $10.4M in Q1 2021. 99 funds tracked by Wall St. Rank hold NUVB as of Q2 2021.

  • Alyeska Investment Group reported no remaining Nuvation Bio position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 1,000,000 Nuvation Bio shares in Q2 2021, an estimated $10.4M.
  • Alyeska Investment Group first reported a position in Nuvation Bio in Q4 2020 and held it in 2 quarters.
  • Alyeska Investment Group's Nuvation Bio position peaked at $10.4M in Q1 2021.
  • 99 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.